Evaluating targeted combination therapies in EGFR wild-type non-small-cell lung cancer using mass spectrometry-based proteomics
Survival for non-small cell lung cancer (NSCLC) patients has been significantly improved by epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with EGFR mutations. However, certain subpopulations of NSCLC patients with EGFR wild-type (wt) status have been shown to also respond to EGFR-TKIs. In an effort to stratify EGFRwt tumors, our group discovered in previous